Abstract: TH-PO751
Preliminary In Vitro Biocompatibility Test on a New Wearable/Portable Device for Extracorporeal Blood Ultrafiltration
Session Information
- Bioengineering
October 25, 2018 | Location: Exhibit Hall, San Diego Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Bioengineering
- 300 Bioengineering
Authors
- Neri, Mauro, Department of Management and Engineering, Vicenza, VI, Italy
- Pomare' Montin, Diego, IRRIV, Vicenza, Italy
- Boscariol, Paolo, Università degli Studi di Padova, Vicenza, Italy
- Boschetti, Giovanni, University of Padova, Vicenza, Italy
- de Cal, Massimo, San Bortolo Hospital, Vicenza, Italy
- Lorenzin, Anna, IRRIV, Vicenza, Italy
- Palomba, Ilaria, Free University of Bolzano-Bozen, Bolzano, Italy
- Richiedei, Dario, Università degli Studi di Padova, Vicenza, Italy
- Trevisani, Alberto, Università degli Studi di Padova, Vicenza, Italy
- Ronco, Claudio, Ospedale "S. Bortolo" AZ. ULSS 6, Vicenza, Italy
Background
Development of a portable/wearable device for extracorporeal blood ultrafiltration (UF) would lead to impressive clinical,social and economic benefits for patients suffering of chronic kidney disease.
This work presents a new prototype of a wearable device for blood UF, named RAP, able to remove excess fluids from fluid overload patients with chronic kidney disease, and a preliminary in vitro test of potential induced cytotoxicity by measuring apoptosis and necrosis in monocytes
cell line due to indirect contact with the device.
Methods
The RAP has been developed as a backpack/trolley configuration. This original layout guarantees the best compromise between miniaturization and ergonomics, introducing an original positioning of many components in 3 independent panels:(a) disposable components,(b) non-disposable devices and (c) electronics. The device has been equipped with a power-bank able to last almost 6 hours and a device for remote monitoring.
Cytotoxicity test was performed by circulating, through the RAP, complete RPMI medium. Monocytes were incubated for 24h in samples taken after 0', 30', 60'. 180' and 360'.
Results
RAP and its design are shown in Figure 1,where also the non-disposable panel and the disposable one, manufactured with addictive technology, are shown. As shown in Figure 2, no inductions of increased necrosis or apoptosis on monocytes with respect to control appeared during a 6h-treatment.
Conclusion
RAP is a new, innovative wearable device for blood ultrafiltration. Arrangement of components can simplify the preparation of the device. Cytotoxic tests demonstrate no induction of cells necrosis or apoptosis. RAP is now ready for human trial.
Funding
- Private Foundation Support